<DOC>
	<DOCNO>NCT01215474</DOCNO>
	<brief_summary>While current mutational analysis comprise exon 19 21 majority EGFR-mutations occur , study aim investigate relevance exon 18 20 mutation . Therefore , investigator analyse 500 routine tumor sample respect mention exon correlate result clinical outcome . This approach enable u potentially identify patient might future benefit target therapy ( EGFR-inhibition ) .</brief_summary>
	<brief_title>Pathomolecular Analysis Rare EGFR Mutations Advanced NSCLC</brief_title>
	<detailed_description />
	<criteria>NSCLC Stadium IIIIV NSCLC different stadium</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>